Loss of ribonuclease DIS3 hampers genome integrity in myeloma by disrupting DNA:RNA hybrid metabolism.


Journal

The EMBO journal
ISSN: 1460-2075
Titre abrégé: EMBO J
Pays: England
ID NLM: 8208664

Informations de publication

Date de publication:
17 11 2022
Historique:
revised: 25 07 2022
received: 16 02 2021
accepted: 23 09 2022
pubmed: 11 10 2022
medline: 22 11 2022
entrez: 10 10 2022
Statut: ppublish

Résumé

The ribonuclease DIS3 is one of the most frequently mutated genes in the hematological cancer multiple myeloma, yet the basis of its tumor suppressor function in this disease remains unclear. Herein, exploiting the TCGA dataset, we found that DIS3 plays a prominent role in the DNA damage response. DIS3 inactivation causes genomic instability by increasing mutational load, and a pervasive accumulation of DNA:RNA hybrids that induces genomic DNA double-strand breaks (DSBs). DNA:RNA hybrid accumulation also prevents binding of the homologous recombination (HR) machinery to double-strand breaks, hampering DSB repair. DIS3-inactivated cells become sensitive to PARP inhibitors, suggestive of a defect in homologous recombination repair. Accordingly, multiple myeloma patient cells mutated for DIS3 harbor an increased mutational burden and a pervasive overexpression of pro-inflammatory interferon, correlating with the accumulation of DNA:RNA hybrids. We propose DIS3 loss in myeloma to be a driving force for tumorigenesis via DNA:RNA hybrid-dependent enhanced genome instability and increased mutational rate. At the same time, DIS3 loss represents a liability that might be therapeutically exploited in patients whose cancer cells harbor DIS3 mutations.

Identifiants

pubmed: 36215697
doi: 10.15252/embj.2021108040
pmc: PMC9670201
doi:

Substances chimiques

Ribonucleases EC 3.1.-
DNA 9007-49-2
RNA 63231-63-0
DIS3 protein, human EC 3.1.13.-
Exosome Multienzyme Ribonuclease Complex EC 3.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e108040

Informations de copyright

© 2022 The Authors. Published under the terms of the CC BY NC ND 4.0 license.

Références

EMBO J. 2010 Jul 21;29(14):2342-57
pubmed: 20531386
Genome Res. 2015 Nov;25(11):1622-33
pubmed: 26294688
Genes Dev. 2014 Jul 1;28(13):1384-96
pubmed: 24990962
Cell. 2016 Nov 3;167(4):1001-1013.e7
pubmed: 27881299
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Mol Cell. 2015 Feb 19;57(4):636-647
pubmed: 25699710
Nature. 2011 Mar 24;471(7339):467-72
pubmed: 21430775
Cancer Res. 1997 Apr 1;57(7):1222-7
pubmed: 9102202
J Mol Biol. 2018 Feb 2;430(3):272-284
pubmed: 29289567
Noncoding RNA. 2018;4(1):
pubmed: 29629374
EMBO J. 2010 Apr 21;29(8):1446-57
pubmed: 20360682
Cell Rep. 2015 Apr 21;11(3):460-73
pubmed: 25865892
Mol Cell. 2012 Mar 30;45(6):814-25
pubmed: 22387027
Oncotarget. 2015 Sep 22;6(28):26129-41
pubmed: 26305418
Nucleic Acids Res. 2017 Oct 13;45(18):10672-10692
pubmed: 28977560
Nat Rev Mol Cell Biol. 2022 Aug;23(8):521-540
pubmed: 35459910
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Nat Rev Cancer. 2003 Jan;3(1):23-34
pubmed: 12509764
J Mol Recognit. 2013 Aug;26(8):376-81
pubmed: 23784994
Blood. 2012 Aug 2;120(5):1077-86
pubmed: 22573403
Biomolecules. 2015 Jul 17;5(3):1515-39
pubmed: 26193331
Prostate Cancer Prostatic Dis. 2020 Dec;23(4):549-560
pubmed: 32367009
Trends Cell Biol. 2015 Sep;25(9):514-22
pubmed: 26045257
World J Biol Chem. 2012 Jan 26;3(1):7-26
pubmed: 22312453
Cell Rep. 2019 Mar 5;26(10):2779-2791.e5
pubmed: 30840897
Nature. 2014 Jul 17;511(7509):362-5
pubmed: 24896180
Nat Struct Mol Biol. 2011 Sep 04;18(10):1132-8
pubmed: 21892171
EMBO J. 1996 Jun 17;15(12):3135-43
pubmed: 8670814
Mol Cell. 2011 Jun 24;42(6):794-805
pubmed: 21700224
DNA Repair (Amst). 2014 Jul;19:84-94
pubmed: 24746923
Nat Rev Clin Oncol. 2019 Oct;16(10):595-596
pubmed: 31332344
Gynecol Oncol. 2017 Dec;147(3):695-704
pubmed: 29037806
Nat Genet. 2021 Feb;53(2):230-242
pubmed: 33526923
DNA Repair (Amst). 2019 Sep;81:102661
pubmed: 31331819
Nat Rev Genet. 2015 Oct;16(10):583-97
pubmed: 26370899
Br J Haematol. 2015 Apr;169(1):57-70
pubmed: 25521164
Nucleic Acids Res. 2016 Jul 8;44(12):5743-57
pubmed: 27131361
Mol Cell. 2016 Jul 7;63(1):167-78
pubmed: 27373332
J Mol Biol. 2017 Oct 27;429(21):3230-3241
pubmed: 28069372
Cell. 2017 Jun 29;170(1):72-85.e14
pubmed: 28666126
Mol Cell. 2003 Sep;12(3):711-21
pubmed: 14527416
Nat Rev Dis Primers. 2017 Jul 20;3:17046
pubmed: 28726797
Trends Genet. 2016 Dec;32(12):828-838
pubmed: 27793359
Nat Cell Biol. 2009 Nov;11(11):1315-24
pubmed: 19838172
Nucleic Acids Res. 2015 May 26;43(10):5182-93
pubmed: 25925570
Epigenetics Chromatin. 2015 Nov 16;8:46
pubmed: 26579211
Nat Commun. 2019 May 13;10(1):2135
pubmed: 31086179
Mol Cell. 2018 Aug 16;71(4):487-497.e3
pubmed: 30078723
Oncogene. 2013 Aug 15;32(33):3789-97
pubmed: 23208502
Haematologica. 2019 Nov 14;105(10):2440-2447
pubmed: 33054085
Cell. 2011 Feb 4;144(3):353-63
pubmed: 21255825
Nat Med. 2011 Mar;17(3):283-4
pubmed: 21383736
Nature. 2014 Oct 16;514(7522):389-93
pubmed: 25119026
Cancer Cell. 2014 Jan 13;25(1):91-101
pubmed: 24434212
EMBO Rep. 2009 Aug;10(8):887-93
pubmed: 19557000
Genes Dev. 2019 Aug 1;33(15-16):1008-1026
pubmed: 31123061
Int J Cancer. 2017 Apr 1;140(7):1545-1550
pubmed: 27943282
Nat Commun. 2014;5:2997
pubmed: 24429703
Mol Cell. 2011 Dec 23;44(6):978-88
pubmed: 22195970
Science. 2013 Feb 15;339(6121):786-91
pubmed: 23258413
Nat Rev Cancer. 2004 Apr;4(4):266-76
pubmed: 15057286
Nat Med. 2014 Jun;20(6):599-606
pubmed: 24813251
EMBO J. 2022 Nov 17;41(22):e108040
pubmed: 36215697
Science. 2011 Dec 16;334(6062):1518-24
pubmed: 22174245
Science. 2008 Dec 19;322(5909):1851-4
pubmed: 19056938
Cell Rep. 2014 Jun 26;7(6):2006-18
pubmed: 24931610
Hum Mol Genet. 2015 Dec 15;24(24):7097-110
pubmed: 26423459
Nat Rev Cancer. 2004 Oct;4(10):814-9
pubmed: 15510162
Nucleic Acids Res. 2018 Feb 28;46(4):1912-1926
pubmed: 29315404
EMBO J. 2017 Dec 1;36(23):3532-3547
pubmed: 29074626
Nat Commun. 2018 Feb 7;9(1):532
pubmed: 29416038
Genes Dev. 2013 Oct 15;27(20):2227-32
pubmed: 24105744
Nat Genet. 2017 Oct;49(10):1476-1486
pubmed: 28825726
Nature. 2012 Aug 9;488(7410):231-5
pubmed: 22722852
J Cell Sci. 2005 May 1;118(Pt 9):2043-55
pubmed: 15840649
Nat Struct Mol Biol. 2014 Oct;21(10):919-26
pubmed: 25240800
Nat Struct Mol Biol. 2014 Apr;21(4):366-74
pubmed: 24658350
Mol Cell. 2011 Jan 7;41(1):21-32
pubmed: 21211720
Cancer Res. 2019 Jan 15;79(2):311-319
pubmed: 30482774
Nucleic Acids Res. 2011 Sep 1;39(16):7179-93
pubmed: 21596787
Curr Opin Struct Biol. 2014 Feb;24:132-40
pubmed: 24525139
Genome Biol. 2006;7(10):R100
pubmed: 17076895
Nat Commun. 2018 Feb 7;9(1):533
pubmed: 29416069
Cancer Discov. 2015 Sep;5(9):972-87
pubmed: 26080835

Auteurs

Ilaria Gritti (I)

Functional Genomics of Cancer Unit, Division of Experimental Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, Italy.

Veronica Basso (V)

Division of Immunology, Transplantation and Infectious Disease, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, Italy.

Darawan Rinchai (D)

Cancer Research Department, Sidra Medicine, Doha, Qatar.

Federica Corigliano (F)

Functional Genomics of Cancer Unit, Division of Experimental Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, Italy.

Silvia Pivetti (S)

Functional Genomics of Cancer Unit, Division of Experimental Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, Italy.

Marco Gaviraghi (M)

Functional Genomics of Cancer Unit, Division of Experimental Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, Italy.

Dalia Rosano (D)

Functional Genomics of Cancer Unit, Division of Experimental Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, Italy.

Davide Mazza (D)

Experimental Imaging Center, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, Italy.

Sara Barozzi (S)

IFOM, The FIRC Institute of Molecular Oncology, Milano, Italy.

Marco Roncador (M)

Department of Data Sciences, Dana Farber Cancer Institute, Boston, MA, USA.
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Giovanni Parmigiani (G)

Department of Data Sciences, Dana Farber Cancer Institute, Boston, MA, USA.
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Gaelle Legube (G)

MCD, Centre de Biologie Intégrative (CBI), CNRS, University of Toulouse, Toulouse, France.

Dario Parazzoli (D)

IFOM, The FIRC Institute of Molecular Oncology, Milano, Italy.

Davide Cittaro (D)

Center for Omics Sciences @OSR (COSR), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, Italy.

Davide Bedognetti (D)

Cancer Research Department, Sidra Medicine, Doha, Qatar.
Dipartimento di Medicina Interna e Specialità Mediche, Università degli Studi di Genova, Genoa, Italy.

Anna Mondino (A)

Division of Immunology, Transplantation and Infectious Disease, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, Italy.

Simona Segalla (S)

Functional Genomics of Cancer Unit, Division of Experimental Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, Italy.

Giovanni Tonon (G)

Functional Genomics of Cancer Unit, Division of Experimental Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, Italy.
Center for Omics Sciences @OSR (COSR), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milano, Italy.
Università Vita-Salute San Raffaele, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH